CureVac (NASDAQ:CVAC) Trading Up 5%

CureVac (NASDAQ:CVAC) shares shot up 5% on Monday . The company traded as high as $3.57 and last traded at $3.57. 60,733 shares were traded during mid-day trading, a decline of 94% from the average session volume of 987,263 shares. The stock had previously closed at $3.40.

Analyst Ratings Changes

Several research firms have issued reports on CVAC. Guggenheim reaffirmed a “neutral” rating on shares of CureVac in a report on Friday, April 5th. Leerink Partnrs cut CureVac from an “outperform” rating to a “market perform” rating in a report on Thursday, April 25th. Finally, SVB Leerink cut CureVac from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $12.00 to $4.00 in a report on Thursday, April 25th.

CureVac Price Performance

The company has a fifty day simple moving average of $3.41 and a 200-day simple moving average of $3.50. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.25 and a quick ratio of 2.09. The company has a market cap of $756.71 million, a P/E ratio of -2.55 and a beta of 2.64.

CureVac (NASDAQ:CVAC) last issued its earnings results on Thursday, May 23rd. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.12). The business had revenue of $13.43 million during the quarter, compared to analyst estimates of $14.51 million. CureVac had a negative return on equity of 49.22% and a negative net margin of 463.49%. On average, sell-side analysts predict that CureVac will post -1.11 earnings per share for the current year.

Hedge Funds Weigh In On CureVac

Several institutional investors and hedge funds have recently bought and sold shares of CVAC. Platinum Investment Management Ltd. grew its position in CureVac by 37.1% during the fourth quarter. Platinum Investment Management Ltd. now owns 497,906 shares of the company’s stock valued at $2,096,000 after purchasing an additional 134,626 shares in the last quarter. Jump Financial LLC acquired a new position in shares of CureVac in the fourth quarter worth $346,000. Tidal Investments LLC acquired a new position in shares of CureVac in the first quarter worth $175,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of CureVac during the fourth quarter worth $160,000. Finally, Aristides Capital LLC purchased a new position in CureVac in the fourth quarter valued at about $100,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.